Jyong Biotech（MENS）株式概要科学主導型のバイオテクノロジー企業であるJyong Biotech Ltd.は、米国、欧州連合（EU）、およびアジアにおいて、泌尿器系疾患の治療を目的とした植物由来医薬品の開発および商業化に取り組んでいます。 詳細MENS ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析マイナスの株主資本 キャッシュランウェイが1年未満である 収益が 100 万ドル未満 ( $0 )すべてのリスクチェックを見るMENS Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW478,154 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA478,154 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$2.64該当なし内在価値ディスカウントEst. Revenue$PastFuture-7m12016201920222025202620282031Revenue US$1.0Earnings US$0.2AdvancedSet Fair ValueView all narrativesJyong Biotech Ltd. 競合他社OnKure TherapeuticsSymbol: NasdaqGM:OKURMarket cap: US$168.4mArcturus Therapeutics HoldingsSymbol: NasdaqGM:ARCTMarket cap: US$170.3mCorbus Pharmaceuticals HoldingsSymbol: NasdaqCM:CRBPMarket cap: US$166.4mAlectorSymbol: NasdaqGS:ALECMarket cap: US$171.0m価格と性能株価の高値、安値、推移の概要Jyong Biotech過去の株価現在の株価US$2.6452週高値US$67.0052週安値US$1.43ベータ01ヶ月の変化66.04%3ヶ月変化16.30%1年変化-76.32%3年間の変化n/a5年間の変化n/aIPOからの変化-73.89%最新ニュースお知らせ • Jul 02Jyong Biotech Showcases Botanical Drug Portfolio At BIO 2026 International ConventionJyong Biotech Ltd. participated in the BIO International Convention (BIO 2026), held in San Diego, California, from June 22 to June 25, 2026. Jyong Biotech once again exhibited at the Taiwan Pavilion. The Company conducted in-depth discussions with global pharmaceutical companies, investment institutions, and industry partners and had the opportunity to present the Company and its assets to them. During the convention, Jyong Biotech presented its botanical new drug candidate, Botreso (API-1), to international pharmaceutical companies as the Company continues advancing global licensing discussions. Targeting benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), the Company has conducted four Phase III clinical trials for Botreso across the United States and Taiwan. The Company believes the drug candidate offers a potentially attractive solution for long-term treatment needs, backed by its proven safety, tolerability, and clinical profile. Driven by an aging global population and rising obesity rates, the BPH and LUTS market continues to expand, with the number of BPH patients projected to grow by 35% to 40% between 2021 and 2035 according to the Global Burden of Disease (GBD 2021) study and BMC Urology. Jyong Biotech is accelerating its New Drug Application (NDA) preparations and global licensing plans. Supported by initial licensing agreement and active discussions with several pharmaceutical partners, the Company aims to expedite commercialization in key markets—including the US, Europe, and Asia—through regional licensing and strategic alliances. As of the date of this press release, Botreso and PCP remain investigational new drug candidates and have not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.お知らせ • Apr 30+ 1 more updateJyong Biotech Ltd Updates Market Access Strategy for Innovative Botanical DrugsJyong Biotech Ltd. had advanced the market access strategies for its innovative plant-based drugs Botreso and PCP, after an analysis of their clinical efficacy and competitive advantages. As previously announced, its first core product, Botreso, has completed four Phase III clinical trials (API-1) in the United States and Taiwan while its second core product, PCP, has successfully completed its Phase II clinical trial. Overall clinical data indicates that Jyong Biotech's innovative botanical drugs demonstrate significant differentiated advantages over currently prescribed synthetic chemical drugs. During the clinical trials – a one-year medication period for Botreso (Phase III) and a two-year period for PCP (Phase II) – no drug-related serious adverse events were observed, indicating excellent safety and tolerability. In contrast, current synthetic chemical drugs for BPH treatment are frequently accompanied by side effects such as orthostatic hypotension, erectile dysfunction, and decreased libido. Regulatory and research institutions have associated some synthetic alternatives with serious risks, prompting the US FDA to issue safety announcements regarding high-grade prostate cancer and depression in 2011, and to add suicidal ideation to adverse reaction lists in 2022, alongside independent research linking them to cardiac failure in 2021. Large-scale international clinical trials have shown that while some synthetic drugs for BPH treatment reduce overall prostate cancer incidence, they may paradoxically increase the proportion of high-grade prostate cancer (Gleason Score = 7) when cancer does occur, raising significant clinical safety concerns. The PCP Phase II trial was a rare large-scale, long-term study in Taiwan, conducted across 20 major hospitals. It involved 135 urologists (representing more than one-tenth of the profession in Taiwan) and 702 subjects over a two-year period. It represents one of the world's first clinical trials of a botanical new drug conducted in Taiwan specifically for prostate cancer prevention. Results indicated that PCP shows a trend in reducing both overall prostate cancer incidence and the risk of high-grade prostate cancer, effectively addressing medical community concerns regarding the risks of current therapies. Based on clinical data from the clinical trials conducted by the Company, the Company believes that it is establishing a differentiated product positioning: Improves Lower Urinary Tract Symptoms (LUTS): Effectively addresses symptoms associated with enlarged prostates. Prostate Cancer Prevention: Demonstrates preventative clinical potential. Metabolic and Cardiovascular Protection: Reduces triglycerides (P=0.05), significantly lowers total cholesterol and LDL (bad cholesterol) (P. This integrated approach provides benefits without negatively affecting blood pressure, liver function, or kidney function. The Company believes that such a comprehensive profile – combining treatment, prevention, and metabolic management – is highly uncommon among current prostate medications and holds strong appeal for men over the age of 40. Due to the inherent complexity and diversity of their compositions, quality control for botanical new drugs is significantly more challenging than for small-molecule chemical drugs. Jianyong Biotech believes it has successfully established a comprehensive technological platform that includes: The purification and establishment of reference standards. The development and validation of analytical methods. The execution of validation analyses and verification processes. The Company believes this integrated capability creates a high barrier to entry, rendering the products highly difficult to replicate. Furthermore, it effectively mitigates the risks associated with counterfeiting and generic drug competition, which ultimately helps to extend the period of market exclusivity. As a Botanical New Drug protected by global patents, Jyong Biotech believes its market strategies leverage several key advantages: Pricing Power: The unique metabolic protection and safety profile allow for premium pricing over off-patent generics, making it attractive to out-of-pocket and high-end medical markets. Licensing Potential: The combination of high tolerability, excellent safety (no severe adverse reactions), and multiple clinical benefits makes it an ideal target for international pharmaceutical partnerships. Market Scalability: Extends the product scope from a treatment-oriented approach into the fields of preventative medicine and health management. Globally, over 500 million men aged 50 and above seek treatment for Benign Prostatic Hyperplasia (BPH). The global BPH drug market, valued at $4.1 billion in 2020, is projected to reach $9.8 billion by 2026. While the current treatment market generates approximately $6.5 to $7 billion annually, this figure reflects price reductions due to patent expirations; if valued at on-patent pricing, this market potential exceeds $20 billion annually. Botreso is the first orally administered botanical new drug developed in Taiwan to receive US FDA Phase III clinical trial (API-1) IND approval and complete four Phase III trials. Holding multi-national invention patents across Asia, the Americas, and the EU, Jyong Biotech has signed letters of intent and investment plans with several international pharmaceutical companies. The company aims to continue expanding strategic, royalty-bearing partnerships to support its global market expansion. As of present day, Botreso and PCP remain investigational new drug candidates and have not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.お知らせ • Mar 28Jyong Biotech Ltd Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS-2Jyong Biotech Ltd. provided an update on the plant-derived innovative drug MCS-2 of its multiple competitive advantages and its potential clinical benefits in the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS). Developed in Taiwan, MCS-2 is the world’s only oral botanical new drug to have completed a global Phase III clinical trial for benign prostatic hyperplasia (BPH). Jyong Biotech has conducted four Phase III clinical trials (API-1) in the U.S. and Taiwan, including two pivotal trials (one in the U.S. and one in Taiwan) and two open-label extension studies (one in the U.S. and one in Taiwan), and completion of the Phase III clinical trial report was achieved in 2017. In the U.S., trials were conducted across 27 centers in 19 states, involving over 200 urologists. In Taiwan, trials took place in 12 major hospitals, including multiple medical centers, with participation from more than 70 urologists (over one-tenth of all urologists in Taiwan). Jyong Biotech strictly adheres to FDA guidelines and standards throughout its drug development process. MCS-2 (API-1) has completed Phase I through Phase III clinical validation, along with more than ten international toxicology studies. Across all four Phase III trials in Taiwan and the U.S., the drug demonstrated excellent safety, with no serious adverse events, supporting its suitability for long-term use. The company believes that its core technology significantly enhances bioavailability and enables the development of multiple formulations and indications, including oral formulations, injectable forms, and bladder instillation therapies. These innovations are protected by patents across the Americas, Asia, Europe, and other regions, forming a global portfolio that effectively overcomes existing patent barriers established by major pharmaceutical companies. BPH/LUTS is a common age-related condition affecting hundreds of millions of men worldwide. Current treatments for BPH/LUTS are associated with side effects and drug resistance, impacting patient compliance and satisfaction. There is therefore an urgent unmet need for a safe, long-term therapeutic solution. MCS-2 is being developed to address this gap, offering clear competitive advantages. As of present day, MCS-2 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.お知らせ • Feb 12Jyong Biotech Ltd. Reports Transformative Period of Clinical Validation and Commercialization Efforts: Phase II DataJyong Biotech Ltd. issued a strategic corporate update. This review encapsulates a pivotal period characterized by the successful completion of the Phase II clinical trial for its lead candidate, MCS-8, and the concurrent attempt of its commercial footprint in key Asian markets. The Company believes the convergence of positive oncological endpoints with unexpected metabolic benefits potentially de-risks its pipeline and positions Jyong Biotech at the forefront of preventative medicine. The Company recently achieved an important milestone with the completion of its Phase II randomized, placebo-controlled trial for MCS-8, which enrolled over 700 high-risk subjects across 20 medical centers in Taiwan. As previously disclosed, the study's primary efficacy analysis yielded a statistically significant 27.3% reduction in the overall incidence of prostate cancer in the MCS-8 arm compared to placebo. The data also demonstrated a 17.1% reduction in high-grade prostate cancer. This finding is clinically profound, as high-grade malignancies represent the primary driver of prostate cancer mortality, and historical chemoprevention agents have often struggled to demonstrate safety or efficacy in this specific sub-population. Further pathological stratification revealed a 35.2% reduction in the percentage of positive biopsy cores and a 24.4% reduction in the cancer-positive area within those cores. These metrics suggest that MCS-8 exerts a tangible biological effect on tumor burden and disease progression, potentially offering a superior alternative to the current standard of "active surveillance," which carries the psychological burden of anxiety for patients waiting for disease progression. Furthermore, non-binding strategic alliances in Korea and Vietnam demonstrate commitment to ensuring these innovative therapies reach patients efficiently. The company are moving forward with a clear vision to redefine the standard of care in preventative neurology. As of present day, MCS-2 and MCS-8 remain investigational new drug candidates and have not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.お知らせ • Feb 07Jyong Biotech Ltd. Announces Chief Financial Officer Changes, Effective February 6, 2026Jyong Biotech Ltd. announced that Wei (Vivi) Zhang has been appointed as the Company's Chief Financial Officer, effective February 6, 2026, replacing Alfred Ying. Ms. Wei (Vivi) Zhang is an experienced finance executive with extensive leadership experience in initial public offerings, funds raising and public companies. Most recently, Ms. Wei served as a consultant for a private company in its initial public offering process. Before that, from 2019 to January 2024, she served as Chief Financial Officer and director at Global Mofy AI Limited (f/k/a Global Mofy Metaverse Limited) (listed on Nasdaq since October 2023: GMM). Ms. Zhang received a bachelor's degree in accounting from the University of South Australia and an MBA degree from the University of Oxford.お知らせ • Jan 30Jyong Biotech Subsidiary Announces Phase Ii Clinical Data on Cholesterol and Ldh Indicators for Mcs-8 (Pcp) Indicating Potential in Prostate Cancer Prevention and Metabolic ValueJyong Biotech Ltd. announced updated statistical analyses for key blood biochemical markers from its Phase II clinical trial of MCS-8 (PCP) conducted in Taiwan. The results underscore MCS-8's previously indicated multifaceted clinical and commercial potential beyond its clinical evidence in prostate cancer prevention, showing its potential in helping alleviate high-grade malignancy risk. The data reveals significant new value in metabolic indicators, specifically cholesterol and lactate dehydrogenase (LDH). Building on this momentum, the Company is evaluating the feasibility of expanding MCS-8's indications to include lipid management, atherosclerosis, and cardiovascular diseases--a strategic move aimed at extending the product's lifecycle and significantly capturing a broader market share. The Phase II clinical trial demonstrated that after two years of treatment, subjects receiving MCS-8 showed improved lipid control compared with baseline, including: A statistically significant reduction in total cholesterol levels (P = 0.036); A statistically significant increase in serum lactate dehydrogenase (LDH) levels observed in the placebo group (P = 0.024), while no such increase was observed in the MCS-8 group. LDH is an enzyme widely present in organs and tissues throughout the body, and elevated serum LDH levels are commonly associated with cellular damage or cell death. The absence of LDH elevation in the MCS-8 Group suggests that MCS-8 may not be causing damage or death to the cell. As previously disclosed, the primary efficacy endpoint of the Phase II study showed that, compared with placebo, the MCS-8 group demonstrated a 27.3% reduction in overall prostate cancer incidence. Further pathological analyses demonstrated favorable trends, including a 35.2% reduction in the percentage of positive centers involved at diagnosis and a 24.4% reduction in the percentage of cancer-positive area involved in positive centers, compared with placebo, suggesting improved control of disease progression. Safety data from the previously disclosed analyses showed that long-term administration of MCS-8 for two years did not increase the rate of adverse events. No serious adverse events related to MCS-8 were observed, and no negative effects were identified on liver function, kidney function, or blood pressure. Company believes that the favorable tolerability profile supports the potential suitability of MCS-8 for long-term preventive use. MCS-8 is developed using Jyong Biotech's core patented pharmaceutical composition technology, which Company believes significantly enhances bioavailability and improves physiological efficacy, offering substantial potential for the development of multiple dosage forms and indications.Related research findings have been published in the international journal Nanotechnology and included by Global Medical Discovery institutions in Canada. MCS-8 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction.最新情報をもっと見るRecent updatesお知らせ • Jul 02Jyong Biotech Showcases Botanical Drug Portfolio At BIO 2026 International ConventionJyong Biotech Ltd. participated in the BIO International Convention (BIO 2026), held in San Diego, California, from June 22 to June 25, 2026. Jyong Biotech once again exhibited at the Taiwan Pavilion. The Company conducted in-depth discussions with global pharmaceutical companies, investment institutions, and industry partners and had the opportunity to present the Company and its assets to them. During the convention, Jyong Biotech presented its botanical new drug candidate, Botreso (API-1), to international pharmaceutical companies as the Company continues advancing global licensing discussions. Targeting benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), the Company has conducted four Phase III clinical trials for Botreso across the United States and Taiwan. The Company believes the drug candidate offers a potentially attractive solution for long-term treatment needs, backed by its proven safety, tolerability, and clinical profile. Driven by an aging global population and rising obesity rates, the BPH and LUTS market continues to expand, with the number of BPH patients projected to grow by 35% to 40% between 2021 and 2035 according to the Global Burden of Disease (GBD 2021) study and BMC Urology. Jyong Biotech is accelerating its New Drug Application (NDA) preparations and global licensing plans. Supported by initial licensing agreement and active discussions with several pharmaceutical partners, the Company aims to expedite commercialization in key markets—including the US, Europe, and Asia—through regional licensing and strategic alliances. As of the date of this press release, Botreso and PCP remain investigational new drug candidates and have not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.お知らせ • Apr 30+ 1 more updateJyong Biotech Ltd Updates Market Access Strategy for Innovative Botanical DrugsJyong Biotech Ltd. had advanced the market access strategies for its innovative plant-based drugs Botreso and PCP, after an analysis of their clinical efficacy and competitive advantages. As previously announced, its first core product, Botreso, has completed four Phase III clinical trials (API-1) in the United States and Taiwan while its second core product, PCP, has successfully completed its Phase II clinical trial. Overall clinical data indicates that Jyong Biotech's innovative botanical drugs demonstrate significant differentiated advantages over currently prescribed synthetic chemical drugs. During the clinical trials – a one-year medication period for Botreso (Phase III) and a two-year period for PCP (Phase II) – no drug-related serious adverse events were observed, indicating excellent safety and tolerability. In contrast, current synthetic chemical drugs for BPH treatment are frequently accompanied by side effects such as orthostatic hypotension, erectile dysfunction, and decreased libido. Regulatory and research institutions have associated some synthetic alternatives with serious risks, prompting the US FDA to issue safety announcements regarding high-grade prostate cancer and depression in 2011, and to add suicidal ideation to adverse reaction lists in 2022, alongside independent research linking them to cardiac failure in 2021. Large-scale international clinical trials have shown that while some synthetic drugs for BPH treatment reduce overall prostate cancer incidence, they may paradoxically increase the proportion of high-grade prostate cancer (Gleason Score = 7) when cancer does occur, raising significant clinical safety concerns. The PCP Phase II trial was a rare large-scale, long-term study in Taiwan, conducted across 20 major hospitals. It involved 135 urologists (representing more than one-tenth of the profession in Taiwan) and 702 subjects over a two-year period. It represents one of the world's first clinical trials of a botanical new drug conducted in Taiwan specifically for prostate cancer prevention. Results indicated that PCP shows a trend in reducing both overall prostate cancer incidence and the risk of high-grade prostate cancer, effectively addressing medical community concerns regarding the risks of current therapies. Based on clinical data from the clinical trials conducted by the Company, the Company believes that it is establishing a differentiated product positioning: Improves Lower Urinary Tract Symptoms (LUTS): Effectively addresses symptoms associated with enlarged prostates. Prostate Cancer Prevention: Demonstrates preventative clinical potential. Metabolic and Cardiovascular Protection: Reduces triglycerides (P=0.05), significantly lowers total cholesterol and LDL (bad cholesterol) (P. This integrated approach provides benefits without negatively affecting blood pressure, liver function, or kidney function. The Company believes that such a comprehensive profile – combining treatment, prevention, and metabolic management – is highly uncommon among current prostate medications and holds strong appeal for men over the age of 40. Due to the inherent complexity and diversity of their compositions, quality control for botanical new drugs is significantly more challenging than for small-molecule chemical drugs. Jianyong Biotech believes it has successfully established a comprehensive technological platform that includes: The purification and establishment of reference standards. The development and validation of analytical methods. The execution of validation analyses and verification processes. The Company believes this integrated capability creates a high barrier to entry, rendering the products highly difficult to replicate. Furthermore, it effectively mitigates the risks associated with counterfeiting and generic drug competition, which ultimately helps to extend the period of market exclusivity. As a Botanical New Drug protected by global patents, Jyong Biotech believes its market strategies leverage several key advantages: Pricing Power: The unique metabolic protection and safety profile allow for premium pricing over off-patent generics, making it attractive to out-of-pocket and high-end medical markets. Licensing Potential: The combination of high tolerability, excellent safety (no severe adverse reactions), and multiple clinical benefits makes it an ideal target for international pharmaceutical partnerships. Market Scalability: Extends the product scope from a treatment-oriented approach into the fields of preventative medicine and health management. Globally, over 500 million men aged 50 and above seek treatment for Benign Prostatic Hyperplasia (BPH). The global BPH drug market, valued at $4.1 billion in 2020, is projected to reach $9.8 billion by 2026. While the current treatment market generates approximately $6.5 to $7 billion annually, this figure reflects price reductions due to patent expirations; if valued at on-patent pricing, this market potential exceeds $20 billion annually. Botreso is the first orally administered botanical new drug developed in Taiwan to receive US FDA Phase III clinical trial (API-1) IND approval and complete four Phase III trials. Holding multi-national invention patents across Asia, the Americas, and the EU, Jyong Biotech has signed letters of intent and investment plans with several international pharmaceutical companies. The company aims to continue expanding strategic, royalty-bearing partnerships to support its global market expansion. As of present day, Botreso and PCP remain investigational new drug candidates and have not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.お知らせ • Mar 28Jyong Biotech Ltd Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS-2Jyong Biotech Ltd. provided an update on the plant-derived innovative drug MCS-2 of its multiple competitive advantages and its potential clinical benefits in the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS). Developed in Taiwan, MCS-2 is the world’s only oral botanical new drug to have completed a global Phase III clinical trial for benign prostatic hyperplasia (BPH). Jyong Biotech has conducted four Phase III clinical trials (API-1) in the U.S. and Taiwan, including two pivotal trials (one in the U.S. and one in Taiwan) and two open-label extension studies (one in the U.S. and one in Taiwan), and completion of the Phase III clinical trial report was achieved in 2017. In the U.S., trials were conducted across 27 centers in 19 states, involving over 200 urologists. In Taiwan, trials took place in 12 major hospitals, including multiple medical centers, with participation from more than 70 urologists (over one-tenth of all urologists in Taiwan). Jyong Biotech strictly adheres to FDA guidelines and standards throughout its drug development process. MCS-2 (API-1) has completed Phase I through Phase III clinical validation, along with more than ten international toxicology studies. Across all four Phase III trials in Taiwan and the U.S., the drug demonstrated excellent safety, with no serious adverse events, supporting its suitability for long-term use. The company believes that its core technology significantly enhances bioavailability and enables the development of multiple formulations and indications, including oral formulations, injectable forms, and bladder instillation therapies. These innovations are protected by patents across the Americas, Asia, Europe, and other regions, forming a global portfolio that effectively overcomes existing patent barriers established by major pharmaceutical companies. BPH/LUTS is a common age-related condition affecting hundreds of millions of men worldwide. Current treatments for BPH/LUTS are associated with side effects and drug resistance, impacting patient compliance and satisfaction. There is therefore an urgent unmet need for a safe, long-term therapeutic solution. MCS-2 is being developed to address this gap, offering clear competitive advantages. As of present day, MCS-2 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.お知らせ • Feb 12Jyong Biotech Ltd. Reports Transformative Period of Clinical Validation and Commercialization Efforts: Phase II DataJyong Biotech Ltd. issued a strategic corporate update. This review encapsulates a pivotal period characterized by the successful completion of the Phase II clinical trial for its lead candidate, MCS-8, and the concurrent attempt of its commercial footprint in key Asian markets. The Company believes the convergence of positive oncological endpoints with unexpected metabolic benefits potentially de-risks its pipeline and positions Jyong Biotech at the forefront of preventative medicine. The Company recently achieved an important milestone with the completion of its Phase II randomized, placebo-controlled trial for MCS-8, which enrolled over 700 high-risk subjects across 20 medical centers in Taiwan. As previously disclosed, the study's primary efficacy analysis yielded a statistically significant 27.3% reduction in the overall incidence of prostate cancer in the MCS-8 arm compared to placebo. The data also demonstrated a 17.1% reduction in high-grade prostate cancer. This finding is clinically profound, as high-grade malignancies represent the primary driver of prostate cancer mortality, and historical chemoprevention agents have often struggled to demonstrate safety or efficacy in this specific sub-population. Further pathological stratification revealed a 35.2% reduction in the percentage of positive biopsy cores and a 24.4% reduction in the cancer-positive area within those cores. These metrics suggest that MCS-8 exerts a tangible biological effect on tumor burden and disease progression, potentially offering a superior alternative to the current standard of "active surveillance," which carries the psychological burden of anxiety for patients waiting for disease progression. Furthermore, non-binding strategic alliances in Korea and Vietnam demonstrate commitment to ensuring these innovative therapies reach patients efficiently. The company are moving forward with a clear vision to redefine the standard of care in preventative neurology. As of present day, MCS-2 and MCS-8 remain investigational new drug candidates and have not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.お知らせ • Feb 07Jyong Biotech Ltd. Announces Chief Financial Officer Changes, Effective February 6, 2026Jyong Biotech Ltd. announced that Wei (Vivi) Zhang has been appointed as the Company's Chief Financial Officer, effective February 6, 2026, replacing Alfred Ying. Ms. Wei (Vivi) Zhang is an experienced finance executive with extensive leadership experience in initial public offerings, funds raising and public companies. Most recently, Ms. Wei served as a consultant for a private company in its initial public offering process. Before that, from 2019 to January 2024, she served as Chief Financial Officer and director at Global Mofy AI Limited (f/k/a Global Mofy Metaverse Limited) (listed on Nasdaq since October 2023: GMM). Ms. Zhang received a bachelor's degree in accounting from the University of South Australia and an MBA degree from the University of Oxford.お知らせ • Jan 30Jyong Biotech Subsidiary Announces Phase Ii Clinical Data on Cholesterol and Ldh Indicators for Mcs-8 (Pcp) Indicating Potential in Prostate Cancer Prevention and Metabolic ValueJyong Biotech Ltd. announced updated statistical analyses for key blood biochemical markers from its Phase II clinical trial of MCS-8 (PCP) conducted in Taiwan. The results underscore MCS-8's previously indicated multifaceted clinical and commercial potential beyond its clinical evidence in prostate cancer prevention, showing its potential in helping alleviate high-grade malignancy risk. The data reveals significant new value in metabolic indicators, specifically cholesterol and lactate dehydrogenase (LDH). Building on this momentum, the Company is evaluating the feasibility of expanding MCS-8's indications to include lipid management, atherosclerosis, and cardiovascular diseases--a strategic move aimed at extending the product's lifecycle and significantly capturing a broader market share. The Phase II clinical trial demonstrated that after two years of treatment, subjects receiving MCS-8 showed improved lipid control compared with baseline, including: A statistically significant reduction in total cholesterol levels (P = 0.036); A statistically significant increase in serum lactate dehydrogenase (LDH) levels observed in the placebo group (P = 0.024), while no such increase was observed in the MCS-8 group. LDH is an enzyme widely present in organs and tissues throughout the body, and elevated serum LDH levels are commonly associated with cellular damage or cell death. The absence of LDH elevation in the MCS-8 Group suggests that MCS-8 may not be causing damage or death to the cell. As previously disclosed, the primary efficacy endpoint of the Phase II study showed that, compared with placebo, the MCS-8 group demonstrated a 27.3% reduction in overall prostate cancer incidence. Further pathological analyses demonstrated favorable trends, including a 35.2% reduction in the percentage of positive centers involved at diagnosis and a 24.4% reduction in the percentage of cancer-positive area involved in positive centers, compared with placebo, suggesting improved control of disease progression. Safety data from the previously disclosed analyses showed that long-term administration of MCS-8 for two years did not increase the rate of adverse events. No serious adverse events related to MCS-8 were observed, and no negative effects were identified on liver function, kidney function, or blood pressure. Company believes that the favorable tolerability profile supports the potential suitability of MCS-8 for long-term preventive use. MCS-8 is developed using Jyong Biotech's core patented pharmaceutical composition technology, which Company believes significantly enhances bioavailability and improves physiological efficacy, offering substantial potential for the development of multiple dosage forms and indications.Related research findings have been published in the international journal Nanotechnology and included by Global Medical Discovery institutions in Canada. MCS-8 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction.Seeking Alpha • Nov 27Jyong Biotech: Speculative BPH And Prostate Cancer Prevention StorySummary Jyong Biotech develops plant-derived carotenoid drugs targeting BPH/LUTS with MCS-2 and prostate cancer prevention. The main asset is MCS-2, but they also have MCS-8 and IC in earlier clinical stages. MCS-8’s Phase 2 data showed a reduction in prostate cancer incidence. Yet, MENS’ main priority is with MCS-2, which targets a large BPH market and previously failed its Phase 3 trials. MCS-2 also previously withdrew its NDA for this asset, which I think should make investors cautious and probably deserves a discount on the stock. I feel MENS’ valuation seems very optimistic compared to its financials and approval prospects with MCS-2. Hence, I remain neutral at these levels. Read the full article on Seeking Alphaお知らせ • Nov 22Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 with Positive OutcomesJyong Biotech Ltd. announced that it has achieved another milestone in the development of its plant-derived new drug MCS-8 (PCP). The Company has completed the statistical analysis of the primary efficacy endpoints in its ongoing Phase II clinical trial conducted in Taiwan, following the randomized and placebo-controlled trial conducted to over 700 high-risk subjects enrolled into the Phase II clinical trial since its commencement. The data indicated that, compared with placebo, MCS-8 (PC P) demonstrated lower incidence rates of prostate cancer and high-grade prostate cancer (Total Gleason Score 7) with good overall tolerability, which lays an important foundation for potential future multinational Phase III clinical trials. The MCS-8 (PCp) Phase II study was a randomized, placebo-controlled trial conducted across 20 hospitals in Taiwan with participation from over 130 urologists--representing more than one-tenth of all urologists nationwide. The trial enrolled more than 700 high-risk subjects, each receiving two years of treatment (either MCS-8 (PCC) or placebo). Key findings showed the following: Primary efficacy endpoint: Compared with placebo, the MCS-8 group indicated a 27.3% reduction in prostate cancer incidence. Secondary efficacy endpoint: Based on maximum Gleason score, the incidence of high-grade prostate cancer (Total Gleason Score 7) showed a 17.1% reduction compared with placebo. Safety assessments also showed: Two-year administration of MCS-8 did not increase adverse event rates, No serious adverse events related to MCS-8 were observed, No negative impact on liver function (AST, ALT), kidney function (BUN, Creatinine), fasting glucose, or blood pressure (systolic/diastolic). Moreover, in the placebo group, fasting glucose significantly increased (P = 0.022), and the triglycerides (TG), HDL showed no significant differences. However, in the MCS-8 group, observed favorable lipid-modulating trends after two years of treatment compared with baseline: TG decreased (P = 0.05) LDL significantly decreased (P = 0.018) and HDL significantly increased (P =0.003). The Company believes that these findings highlight the safety and tolerability of MCS-8 and suggest that there might be potential for future clinical studies in lipid management, atherosclerosis, and cardiovascular diseases. Throughout the development of MCS-8 (PCK), the Company has adhered closely to U.S. FDA guidelines and standards, conducting rigorous scientific validation and clinical testing. MCS-8 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction.お知らせ • Sep 16Jyong Biotech Ltd. Announces Completion of Patient Enrollment of over 700 Subjects in Phase II Clinical Trial of MCS-8 for Prostate Cancer PreventionJyong Biotech Ltd. announced that it has completed patient enrollment in its Phase II clinical trial of MCS-8, an investigational drug candidate for prostate cancer prevention (PCP), with more than 700 high-risk subject who have enrolled into this clinical trial since its commencement. The randomized, placebo-controlled trial is being conducted across 20 hospitals in Taiwan, with the participation of more than 130 urologists. MCS-8 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction. The Company expects to analyze the trial data following completion of the treatment period and will share results in accordance with applicable disclosure requirements.株主還元MENSUS BiotechsUS 市場7D15.3%-1.4%-1.4%1Y-76.3%28.1%16.4%株主還元を見る業界別リターン: MENS過去 1 年間で28.1 % の収益を上げたUS Biotechs業界を下回りました。リターン対市場: MENSは、過去 1 年間で16.4 % のリターンを上げたUS市場を下回りました。価格変動Is MENS's price volatile compared to industry and market?MENS volatilityMENS Average Weekly Movement10.5%Biotechs Industry Average Movement10.2%Market Average Movement7.1%10% most volatile stocks in US Market16.3%10% least volatile stocks in US Market3.2%安定した株価: MENS 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: MENSの 週次ボラティリティ は、過去 1 年間で25%から10%に減少しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト200227Fu-Feng Kuojyongbio.com科学主導型のバイオテクノロジー企業であるJyong Biotech Ltd.は、米国、欧州連合（EU）、およびアジアにおいて、泌尿器系疾患の治療を目的とした植物由来医薬品の開発および商業化に取り組んでいます。 同社は、前立腺肥大症および下部尿路症状の治療薬「ボトレソ」、前立腺がんの治療薬「PCP」、ならびに間質性膀胱炎（IC）および膀胱痛症候群の治療薬「IC」を開発している。同社は2002年に設立され、台湾の新北市に本社を置いている。もっと見るJyong Biotech Ltd. 基礎のまとめJyong Biotech の収益と売上を時価総額と比較するとどうか。MENS 基礎統計学時価総額US$191.52m収益（TTM）-US$4.67m売上高(TTM)n/a0.0xP/Sレシオ-42.0xPER（株価収益率MENS は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計MENS 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$4.67m収益-US$4.67m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.063グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-74.0%MENS の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/22 08:03終値2026/07/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Jyong Biotech Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jul 02Jyong Biotech Showcases Botanical Drug Portfolio At BIO 2026 International ConventionJyong Biotech Ltd. participated in the BIO International Convention (BIO 2026), held in San Diego, California, from June 22 to June 25, 2026. Jyong Biotech once again exhibited at the Taiwan Pavilion. The Company conducted in-depth discussions with global pharmaceutical companies, investment institutions, and industry partners and had the opportunity to present the Company and its assets to them. During the convention, Jyong Biotech presented its botanical new drug candidate, Botreso (API-1), to international pharmaceutical companies as the Company continues advancing global licensing discussions. Targeting benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), the Company has conducted four Phase III clinical trials for Botreso across the United States and Taiwan. The Company believes the drug candidate offers a potentially attractive solution for long-term treatment needs, backed by its proven safety, tolerability, and clinical profile. Driven by an aging global population and rising obesity rates, the BPH and LUTS market continues to expand, with the number of BPH patients projected to grow by 35% to 40% between 2021 and 2035 according to the Global Burden of Disease (GBD 2021) study and BMC Urology. Jyong Biotech is accelerating its New Drug Application (NDA) preparations and global licensing plans. Supported by initial licensing agreement and active discussions with several pharmaceutical partners, the Company aims to expedite commercialization in key markets—including the US, Europe, and Asia—through regional licensing and strategic alliances. As of the date of this press release, Botreso and PCP remain investigational new drug candidates and have not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.
お知らせ • Apr 30+ 1 more updateJyong Biotech Ltd Updates Market Access Strategy for Innovative Botanical DrugsJyong Biotech Ltd. had advanced the market access strategies for its innovative plant-based drugs Botreso and PCP, after an analysis of their clinical efficacy and competitive advantages. As previously announced, its first core product, Botreso, has completed four Phase III clinical trials (API-1) in the United States and Taiwan while its second core product, PCP, has successfully completed its Phase II clinical trial. Overall clinical data indicates that Jyong Biotech's innovative botanical drugs demonstrate significant differentiated advantages over currently prescribed synthetic chemical drugs. During the clinical trials – a one-year medication period for Botreso (Phase III) and a two-year period for PCP (Phase II) – no drug-related serious adverse events were observed, indicating excellent safety and tolerability. In contrast, current synthetic chemical drugs for BPH treatment are frequently accompanied by side effects such as orthostatic hypotension, erectile dysfunction, and decreased libido. Regulatory and research institutions have associated some synthetic alternatives with serious risks, prompting the US FDA to issue safety announcements regarding high-grade prostate cancer and depression in 2011, and to add suicidal ideation to adverse reaction lists in 2022, alongside independent research linking them to cardiac failure in 2021. Large-scale international clinical trials have shown that while some synthetic drugs for BPH treatment reduce overall prostate cancer incidence, they may paradoxically increase the proportion of high-grade prostate cancer (Gleason Score = 7) when cancer does occur, raising significant clinical safety concerns. The PCP Phase II trial was a rare large-scale, long-term study in Taiwan, conducted across 20 major hospitals. It involved 135 urologists (representing more than one-tenth of the profession in Taiwan) and 702 subjects over a two-year period. It represents one of the world's first clinical trials of a botanical new drug conducted in Taiwan specifically for prostate cancer prevention. Results indicated that PCP shows a trend in reducing both overall prostate cancer incidence and the risk of high-grade prostate cancer, effectively addressing medical community concerns regarding the risks of current therapies. Based on clinical data from the clinical trials conducted by the Company, the Company believes that it is establishing a differentiated product positioning: Improves Lower Urinary Tract Symptoms (LUTS): Effectively addresses symptoms associated with enlarged prostates. Prostate Cancer Prevention: Demonstrates preventative clinical potential. Metabolic and Cardiovascular Protection: Reduces triglycerides (P=0.05), significantly lowers total cholesterol and LDL (bad cholesterol) (P. This integrated approach provides benefits without negatively affecting blood pressure, liver function, or kidney function. The Company believes that such a comprehensive profile – combining treatment, prevention, and metabolic management – is highly uncommon among current prostate medications and holds strong appeal for men over the age of 40. Due to the inherent complexity and diversity of their compositions, quality control for botanical new drugs is significantly more challenging than for small-molecule chemical drugs. Jianyong Biotech believes it has successfully established a comprehensive technological platform that includes: The purification and establishment of reference standards. The development and validation of analytical methods. The execution of validation analyses and verification processes. The Company believes this integrated capability creates a high barrier to entry, rendering the products highly difficult to replicate. Furthermore, it effectively mitigates the risks associated with counterfeiting and generic drug competition, which ultimately helps to extend the period of market exclusivity. As a Botanical New Drug protected by global patents, Jyong Biotech believes its market strategies leverage several key advantages: Pricing Power: The unique metabolic protection and safety profile allow for premium pricing over off-patent generics, making it attractive to out-of-pocket and high-end medical markets. Licensing Potential: The combination of high tolerability, excellent safety (no severe adverse reactions), and multiple clinical benefits makes it an ideal target for international pharmaceutical partnerships. Market Scalability: Extends the product scope from a treatment-oriented approach into the fields of preventative medicine and health management. Globally, over 500 million men aged 50 and above seek treatment for Benign Prostatic Hyperplasia (BPH). The global BPH drug market, valued at $4.1 billion in 2020, is projected to reach $9.8 billion by 2026. While the current treatment market generates approximately $6.5 to $7 billion annually, this figure reflects price reductions due to patent expirations; if valued at on-patent pricing, this market potential exceeds $20 billion annually. Botreso is the first orally administered botanical new drug developed in Taiwan to receive US FDA Phase III clinical trial (API-1) IND approval and complete four Phase III trials. Holding multi-national invention patents across Asia, the Americas, and the EU, Jyong Biotech has signed letters of intent and investment plans with several international pharmaceutical companies. The company aims to continue expanding strategic, royalty-bearing partnerships to support its global market expansion. As of present day, Botreso and PCP remain investigational new drug candidates and have not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.
お知らせ • Mar 28Jyong Biotech Ltd Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS-2Jyong Biotech Ltd. provided an update on the plant-derived innovative drug MCS-2 of its multiple competitive advantages and its potential clinical benefits in the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS). Developed in Taiwan, MCS-2 is the world’s only oral botanical new drug to have completed a global Phase III clinical trial for benign prostatic hyperplasia (BPH). Jyong Biotech has conducted four Phase III clinical trials (API-1) in the U.S. and Taiwan, including two pivotal trials (one in the U.S. and one in Taiwan) and two open-label extension studies (one in the U.S. and one in Taiwan), and completion of the Phase III clinical trial report was achieved in 2017. In the U.S., trials were conducted across 27 centers in 19 states, involving over 200 urologists. In Taiwan, trials took place in 12 major hospitals, including multiple medical centers, with participation from more than 70 urologists (over one-tenth of all urologists in Taiwan). Jyong Biotech strictly adheres to FDA guidelines and standards throughout its drug development process. MCS-2 (API-1) has completed Phase I through Phase III clinical validation, along with more than ten international toxicology studies. Across all four Phase III trials in Taiwan and the U.S., the drug demonstrated excellent safety, with no serious adverse events, supporting its suitability for long-term use. The company believes that its core technology significantly enhances bioavailability and enables the development of multiple formulations and indications, including oral formulations, injectable forms, and bladder instillation therapies. These innovations are protected by patents across the Americas, Asia, Europe, and other regions, forming a global portfolio that effectively overcomes existing patent barriers established by major pharmaceutical companies. BPH/LUTS is a common age-related condition affecting hundreds of millions of men worldwide. Current treatments for BPH/LUTS are associated with side effects and drug resistance, impacting patient compliance and satisfaction. There is therefore an urgent unmet need for a safe, long-term therapeutic solution. MCS-2 is being developed to address this gap, offering clear competitive advantages. As of present day, MCS-2 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.
お知らせ • Feb 12Jyong Biotech Ltd. Reports Transformative Period of Clinical Validation and Commercialization Efforts: Phase II DataJyong Biotech Ltd. issued a strategic corporate update. This review encapsulates a pivotal period characterized by the successful completion of the Phase II clinical trial for its lead candidate, MCS-8, and the concurrent attempt of its commercial footprint in key Asian markets. The Company believes the convergence of positive oncological endpoints with unexpected metabolic benefits potentially de-risks its pipeline and positions Jyong Biotech at the forefront of preventative medicine. The Company recently achieved an important milestone with the completion of its Phase II randomized, placebo-controlled trial for MCS-8, which enrolled over 700 high-risk subjects across 20 medical centers in Taiwan. As previously disclosed, the study's primary efficacy analysis yielded a statistically significant 27.3% reduction in the overall incidence of prostate cancer in the MCS-8 arm compared to placebo. The data also demonstrated a 17.1% reduction in high-grade prostate cancer. This finding is clinically profound, as high-grade malignancies represent the primary driver of prostate cancer mortality, and historical chemoprevention agents have often struggled to demonstrate safety or efficacy in this specific sub-population. Further pathological stratification revealed a 35.2% reduction in the percentage of positive biopsy cores and a 24.4% reduction in the cancer-positive area within those cores. These metrics suggest that MCS-8 exerts a tangible biological effect on tumor burden and disease progression, potentially offering a superior alternative to the current standard of "active surveillance," which carries the psychological burden of anxiety for patients waiting for disease progression. Furthermore, non-binding strategic alliances in Korea and Vietnam demonstrate commitment to ensuring these innovative therapies reach patients efficiently. The company are moving forward with a clear vision to redefine the standard of care in preventative neurology. As of present day, MCS-2 and MCS-8 remain investigational new drug candidates and have not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.
お知らせ • Feb 07Jyong Biotech Ltd. Announces Chief Financial Officer Changes, Effective February 6, 2026Jyong Biotech Ltd. announced that Wei (Vivi) Zhang has been appointed as the Company's Chief Financial Officer, effective February 6, 2026, replacing Alfred Ying. Ms. Wei (Vivi) Zhang is an experienced finance executive with extensive leadership experience in initial public offerings, funds raising and public companies. Most recently, Ms. Wei served as a consultant for a private company in its initial public offering process. Before that, from 2019 to January 2024, she served as Chief Financial Officer and director at Global Mofy AI Limited (f/k/a Global Mofy Metaverse Limited) (listed on Nasdaq since October 2023: GMM). Ms. Zhang received a bachelor's degree in accounting from the University of South Australia and an MBA degree from the University of Oxford.
お知らせ • Jan 30Jyong Biotech Subsidiary Announces Phase Ii Clinical Data on Cholesterol and Ldh Indicators for Mcs-8 (Pcp) Indicating Potential in Prostate Cancer Prevention and Metabolic ValueJyong Biotech Ltd. announced updated statistical analyses for key blood biochemical markers from its Phase II clinical trial of MCS-8 (PCP) conducted in Taiwan. The results underscore MCS-8's previously indicated multifaceted clinical and commercial potential beyond its clinical evidence in prostate cancer prevention, showing its potential in helping alleviate high-grade malignancy risk. The data reveals significant new value in metabolic indicators, specifically cholesterol and lactate dehydrogenase (LDH). Building on this momentum, the Company is evaluating the feasibility of expanding MCS-8's indications to include lipid management, atherosclerosis, and cardiovascular diseases--a strategic move aimed at extending the product's lifecycle and significantly capturing a broader market share. The Phase II clinical trial demonstrated that after two years of treatment, subjects receiving MCS-8 showed improved lipid control compared with baseline, including: A statistically significant reduction in total cholesterol levels (P = 0.036); A statistically significant increase in serum lactate dehydrogenase (LDH) levels observed in the placebo group (P = 0.024), while no such increase was observed in the MCS-8 group. LDH is an enzyme widely present in organs and tissues throughout the body, and elevated serum LDH levels are commonly associated with cellular damage or cell death. The absence of LDH elevation in the MCS-8 Group suggests that MCS-8 may not be causing damage or death to the cell. As previously disclosed, the primary efficacy endpoint of the Phase II study showed that, compared with placebo, the MCS-8 group demonstrated a 27.3% reduction in overall prostate cancer incidence. Further pathological analyses demonstrated favorable trends, including a 35.2% reduction in the percentage of positive centers involved at diagnosis and a 24.4% reduction in the percentage of cancer-positive area involved in positive centers, compared with placebo, suggesting improved control of disease progression. Safety data from the previously disclosed analyses showed that long-term administration of MCS-8 for two years did not increase the rate of adverse events. No serious adverse events related to MCS-8 were observed, and no negative effects were identified on liver function, kidney function, or blood pressure. Company believes that the favorable tolerability profile supports the potential suitability of MCS-8 for long-term preventive use. MCS-8 is developed using Jyong Biotech's core patented pharmaceutical composition technology, which Company believes significantly enhances bioavailability and improves physiological efficacy, offering substantial potential for the development of multiple dosage forms and indications.Related research findings have been published in the international journal Nanotechnology and included by Global Medical Discovery institutions in Canada. MCS-8 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction.
お知らせ • Jul 02Jyong Biotech Showcases Botanical Drug Portfolio At BIO 2026 International ConventionJyong Biotech Ltd. participated in the BIO International Convention (BIO 2026), held in San Diego, California, from June 22 to June 25, 2026. Jyong Biotech once again exhibited at the Taiwan Pavilion. The Company conducted in-depth discussions with global pharmaceutical companies, investment institutions, and industry partners and had the opportunity to present the Company and its assets to them. During the convention, Jyong Biotech presented its botanical new drug candidate, Botreso (API-1), to international pharmaceutical companies as the Company continues advancing global licensing discussions. Targeting benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), the Company has conducted four Phase III clinical trials for Botreso across the United States and Taiwan. The Company believes the drug candidate offers a potentially attractive solution for long-term treatment needs, backed by its proven safety, tolerability, and clinical profile. Driven by an aging global population and rising obesity rates, the BPH and LUTS market continues to expand, with the number of BPH patients projected to grow by 35% to 40% between 2021 and 2035 according to the Global Burden of Disease (GBD 2021) study and BMC Urology. Jyong Biotech is accelerating its New Drug Application (NDA) preparations and global licensing plans. Supported by initial licensing agreement and active discussions with several pharmaceutical partners, the Company aims to expedite commercialization in key markets—including the US, Europe, and Asia—through regional licensing and strategic alliances. As of the date of this press release, Botreso and PCP remain investigational new drug candidates and have not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.
お知らせ • Apr 30+ 1 more updateJyong Biotech Ltd Updates Market Access Strategy for Innovative Botanical DrugsJyong Biotech Ltd. had advanced the market access strategies for its innovative plant-based drugs Botreso and PCP, after an analysis of their clinical efficacy and competitive advantages. As previously announced, its first core product, Botreso, has completed four Phase III clinical trials (API-1) in the United States and Taiwan while its second core product, PCP, has successfully completed its Phase II clinical trial. Overall clinical data indicates that Jyong Biotech's innovative botanical drugs demonstrate significant differentiated advantages over currently prescribed synthetic chemical drugs. During the clinical trials – a one-year medication period for Botreso (Phase III) and a two-year period for PCP (Phase II) – no drug-related serious adverse events were observed, indicating excellent safety and tolerability. In contrast, current synthetic chemical drugs for BPH treatment are frequently accompanied by side effects such as orthostatic hypotension, erectile dysfunction, and decreased libido. Regulatory and research institutions have associated some synthetic alternatives with serious risks, prompting the US FDA to issue safety announcements regarding high-grade prostate cancer and depression in 2011, and to add suicidal ideation to adverse reaction lists in 2022, alongside independent research linking them to cardiac failure in 2021. Large-scale international clinical trials have shown that while some synthetic drugs for BPH treatment reduce overall prostate cancer incidence, they may paradoxically increase the proportion of high-grade prostate cancer (Gleason Score = 7) when cancer does occur, raising significant clinical safety concerns. The PCP Phase II trial was a rare large-scale, long-term study in Taiwan, conducted across 20 major hospitals. It involved 135 urologists (representing more than one-tenth of the profession in Taiwan) and 702 subjects over a two-year period. It represents one of the world's first clinical trials of a botanical new drug conducted in Taiwan specifically for prostate cancer prevention. Results indicated that PCP shows a trend in reducing both overall prostate cancer incidence and the risk of high-grade prostate cancer, effectively addressing medical community concerns regarding the risks of current therapies. Based on clinical data from the clinical trials conducted by the Company, the Company believes that it is establishing a differentiated product positioning: Improves Lower Urinary Tract Symptoms (LUTS): Effectively addresses symptoms associated with enlarged prostates. Prostate Cancer Prevention: Demonstrates preventative clinical potential. Metabolic and Cardiovascular Protection: Reduces triglycerides (P=0.05), significantly lowers total cholesterol and LDL (bad cholesterol) (P. This integrated approach provides benefits without negatively affecting blood pressure, liver function, or kidney function. The Company believes that such a comprehensive profile – combining treatment, prevention, and metabolic management – is highly uncommon among current prostate medications and holds strong appeal for men over the age of 40. Due to the inherent complexity and diversity of their compositions, quality control for botanical new drugs is significantly more challenging than for small-molecule chemical drugs. Jianyong Biotech believes it has successfully established a comprehensive technological platform that includes: The purification and establishment of reference standards. The development and validation of analytical methods. The execution of validation analyses and verification processes. The Company believes this integrated capability creates a high barrier to entry, rendering the products highly difficult to replicate. Furthermore, it effectively mitigates the risks associated with counterfeiting and generic drug competition, which ultimately helps to extend the period of market exclusivity. As a Botanical New Drug protected by global patents, Jyong Biotech believes its market strategies leverage several key advantages: Pricing Power: The unique metabolic protection and safety profile allow for premium pricing over off-patent generics, making it attractive to out-of-pocket and high-end medical markets. Licensing Potential: The combination of high tolerability, excellent safety (no severe adverse reactions), and multiple clinical benefits makes it an ideal target for international pharmaceutical partnerships. Market Scalability: Extends the product scope from a treatment-oriented approach into the fields of preventative medicine and health management. Globally, over 500 million men aged 50 and above seek treatment for Benign Prostatic Hyperplasia (BPH). The global BPH drug market, valued at $4.1 billion in 2020, is projected to reach $9.8 billion by 2026. While the current treatment market generates approximately $6.5 to $7 billion annually, this figure reflects price reductions due to patent expirations; if valued at on-patent pricing, this market potential exceeds $20 billion annually. Botreso is the first orally administered botanical new drug developed in Taiwan to receive US FDA Phase III clinical trial (API-1) IND approval and complete four Phase III trials. Holding multi-national invention patents across Asia, the Americas, and the EU, Jyong Biotech has signed letters of intent and investment plans with several international pharmaceutical companies. The company aims to continue expanding strategic, royalty-bearing partnerships to support its global market expansion. As of present day, Botreso and PCP remain investigational new drug candidates and have not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.
お知らせ • Mar 28Jyong Biotech Ltd Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS-2Jyong Biotech Ltd. provided an update on the plant-derived innovative drug MCS-2 of its multiple competitive advantages and its potential clinical benefits in the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS). Developed in Taiwan, MCS-2 is the world’s only oral botanical new drug to have completed a global Phase III clinical trial for benign prostatic hyperplasia (BPH). Jyong Biotech has conducted four Phase III clinical trials (API-1) in the U.S. and Taiwan, including two pivotal trials (one in the U.S. and one in Taiwan) and two open-label extension studies (one in the U.S. and one in Taiwan), and completion of the Phase III clinical trial report was achieved in 2017. In the U.S., trials were conducted across 27 centers in 19 states, involving over 200 urologists. In Taiwan, trials took place in 12 major hospitals, including multiple medical centers, with participation from more than 70 urologists (over one-tenth of all urologists in Taiwan). Jyong Biotech strictly adheres to FDA guidelines and standards throughout its drug development process. MCS-2 (API-1) has completed Phase I through Phase III clinical validation, along with more than ten international toxicology studies. Across all four Phase III trials in Taiwan and the U.S., the drug demonstrated excellent safety, with no serious adverse events, supporting its suitability for long-term use. The company believes that its core technology significantly enhances bioavailability and enables the development of multiple formulations and indications, including oral formulations, injectable forms, and bladder instillation therapies. These innovations are protected by patents across the Americas, Asia, Europe, and other regions, forming a global portfolio that effectively overcomes existing patent barriers established by major pharmaceutical companies. BPH/LUTS is a common age-related condition affecting hundreds of millions of men worldwide. Current treatments for BPH/LUTS are associated with side effects and drug resistance, impacting patient compliance and satisfaction. There is therefore an urgent unmet need for a safe, long-term therapeutic solution. MCS-2 is being developed to address this gap, offering clear competitive advantages. As of present day, MCS-2 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.
お知らせ • Feb 12Jyong Biotech Ltd. Reports Transformative Period of Clinical Validation and Commercialization Efforts: Phase II DataJyong Biotech Ltd. issued a strategic corporate update. This review encapsulates a pivotal period characterized by the successful completion of the Phase II clinical trial for its lead candidate, MCS-8, and the concurrent attempt of its commercial footprint in key Asian markets. The Company believes the convergence of positive oncological endpoints with unexpected metabolic benefits potentially de-risks its pipeline and positions Jyong Biotech at the forefront of preventative medicine. The Company recently achieved an important milestone with the completion of its Phase II randomized, placebo-controlled trial for MCS-8, which enrolled over 700 high-risk subjects across 20 medical centers in Taiwan. As previously disclosed, the study's primary efficacy analysis yielded a statistically significant 27.3% reduction in the overall incidence of prostate cancer in the MCS-8 arm compared to placebo. The data also demonstrated a 17.1% reduction in high-grade prostate cancer. This finding is clinically profound, as high-grade malignancies represent the primary driver of prostate cancer mortality, and historical chemoprevention agents have often struggled to demonstrate safety or efficacy in this specific sub-population. Further pathological stratification revealed a 35.2% reduction in the percentage of positive biopsy cores and a 24.4% reduction in the cancer-positive area within those cores. These metrics suggest that MCS-8 exerts a tangible biological effect on tumor burden and disease progression, potentially offering a superior alternative to the current standard of "active surveillance," which carries the psychological burden of anxiety for patients waiting for disease progression. Furthermore, non-binding strategic alliances in Korea and Vietnam demonstrate commitment to ensuring these innovative therapies reach patients efficiently. The company are moving forward with a clear vision to redefine the standard of care in preventative neurology. As of present day, MCS-2 and MCS-8 remain investigational new drug candidates and have not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.
お知らせ • Feb 07Jyong Biotech Ltd. Announces Chief Financial Officer Changes, Effective February 6, 2026Jyong Biotech Ltd. announced that Wei (Vivi) Zhang has been appointed as the Company's Chief Financial Officer, effective February 6, 2026, replacing Alfred Ying. Ms. Wei (Vivi) Zhang is an experienced finance executive with extensive leadership experience in initial public offerings, funds raising and public companies. Most recently, Ms. Wei served as a consultant for a private company in its initial public offering process. Before that, from 2019 to January 2024, she served as Chief Financial Officer and director at Global Mofy AI Limited (f/k/a Global Mofy Metaverse Limited) (listed on Nasdaq since October 2023: GMM). Ms. Zhang received a bachelor's degree in accounting from the University of South Australia and an MBA degree from the University of Oxford.
お知らせ • Jan 30Jyong Biotech Subsidiary Announces Phase Ii Clinical Data on Cholesterol and Ldh Indicators for Mcs-8 (Pcp) Indicating Potential in Prostate Cancer Prevention and Metabolic ValueJyong Biotech Ltd. announced updated statistical analyses for key blood biochemical markers from its Phase II clinical trial of MCS-8 (PCP) conducted in Taiwan. The results underscore MCS-8's previously indicated multifaceted clinical and commercial potential beyond its clinical evidence in prostate cancer prevention, showing its potential in helping alleviate high-grade malignancy risk. The data reveals significant new value in metabolic indicators, specifically cholesterol and lactate dehydrogenase (LDH). Building on this momentum, the Company is evaluating the feasibility of expanding MCS-8's indications to include lipid management, atherosclerosis, and cardiovascular diseases--a strategic move aimed at extending the product's lifecycle and significantly capturing a broader market share. The Phase II clinical trial demonstrated that after two years of treatment, subjects receiving MCS-8 showed improved lipid control compared with baseline, including: A statistically significant reduction in total cholesterol levels (P = 0.036); A statistically significant increase in serum lactate dehydrogenase (LDH) levels observed in the placebo group (P = 0.024), while no such increase was observed in the MCS-8 group. LDH is an enzyme widely present in organs and tissues throughout the body, and elevated serum LDH levels are commonly associated with cellular damage or cell death. The absence of LDH elevation in the MCS-8 Group suggests that MCS-8 may not be causing damage or death to the cell. As previously disclosed, the primary efficacy endpoint of the Phase II study showed that, compared with placebo, the MCS-8 group demonstrated a 27.3% reduction in overall prostate cancer incidence. Further pathological analyses demonstrated favorable trends, including a 35.2% reduction in the percentage of positive centers involved at diagnosis and a 24.4% reduction in the percentage of cancer-positive area involved in positive centers, compared with placebo, suggesting improved control of disease progression. Safety data from the previously disclosed analyses showed that long-term administration of MCS-8 for two years did not increase the rate of adverse events. No serious adverse events related to MCS-8 were observed, and no negative effects were identified on liver function, kidney function, or blood pressure. Company believes that the favorable tolerability profile supports the potential suitability of MCS-8 for long-term preventive use. MCS-8 is developed using Jyong Biotech's core patented pharmaceutical composition technology, which Company believes significantly enhances bioavailability and improves physiological efficacy, offering substantial potential for the development of multiple dosage forms and indications.Related research findings have been published in the international journal Nanotechnology and included by Global Medical Discovery institutions in Canada. MCS-8 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction.
Seeking Alpha • Nov 27Jyong Biotech: Speculative BPH And Prostate Cancer Prevention StorySummary Jyong Biotech develops plant-derived carotenoid drugs targeting BPH/LUTS with MCS-2 and prostate cancer prevention. The main asset is MCS-2, but they also have MCS-8 and IC in earlier clinical stages. MCS-8’s Phase 2 data showed a reduction in prostate cancer incidence. Yet, MENS’ main priority is with MCS-2, which targets a large BPH market and previously failed its Phase 3 trials. MCS-2 also previously withdrew its NDA for this asset, which I think should make investors cautious and probably deserves a discount on the stock. I feel MENS’ valuation seems very optimistic compared to its financials and approval prospects with MCS-2. Hence, I remain neutral at these levels. Read the full article on Seeking Alpha
お知らせ • Nov 22Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 with Positive OutcomesJyong Biotech Ltd. announced that it has achieved another milestone in the development of its plant-derived new drug MCS-8 (PCP). The Company has completed the statistical analysis of the primary efficacy endpoints in its ongoing Phase II clinical trial conducted in Taiwan, following the randomized and placebo-controlled trial conducted to over 700 high-risk subjects enrolled into the Phase II clinical trial since its commencement. The data indicated that, compared with placebo, MCS-8 (PC P) demonstrated lower incidence rates of prostate cancer and high-grade prostate cancer (Total Gleason Score 7) with good overall tolerability, which lays an important foundation for potential future multinational Phase III clinical trials. The MCS-8 (PCp) Phase II study was a randomized, placebo-controlled trial conducted across 20 hospitals in Taiwan with participation from over 130 urologists--representing more than one-tenth of all urologists nationwide. The trial enrolled more than 700 high-risk subjects, each receiving two years of treatment (either MCS-8 (PCC) or placebo). Key findings showed the following: Primary efficacy endpoint: Compared with placebo, the MCS-8 group indicated a 27.3% reduction in prostate cancer incidence. Secondary efficacy endpoint: Based on maximum Gleason score, the incidence of high-grade prostate cancer (Total Gleason Score 7) showed a 17.1% reduction compared with placebo. Safety assessments also showed: Two-year administration of MCS-8 did not increase adverse event rates, No serious adverse events related to MCS-8 were observed, No negative impact on liver function (AST, ALT), kidney function (BUN, Creatinine), fasting glucose, or blood pressure (systolic/diastolic). Moreover, in the placebo group, fasting glucose significantly increased (P = 0.022), and the triglycerides (TG), HDL showed no significant differences. However, in the MCS-8 group, observed favorable lipid-modulating trends after two years of treatment compared with baseline: TG decreased (P = 0.05) LDL significantly decreased (P = 0.018) and HDL significantly increased (P =0.003). The Company believes that these findings highlight the safety and tolerability of MCS-8 and suggest that there might be potential for future clinical studies in lipid management, atherosclerosis, and cardiovascular diseases. Throughout the development of MCS-8 (PCK), the Company has adhered closely to U.S. FDA guidelines and standards, conducting rigorous scientific validation and clinical testing. MCS-8 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction.
お知らせ • Sep 16Jyong Biotech Ltd. Announces Completion of Patient Enrollment of over 700 Subjects in Phase II Clinical Trial of MCS-8 for Prostate Cancer PreventionJyong Biotech Ltd. announced that it has completed patient enrollment in its Phase II clinical trial of MCS-8, an investigational drug candidate for prostate cancer prevention (PCP), with more than 700 high-risk subject who have enrolled into this clinical trial since its commencement. The randomized, placebo-controlled trial is being conducted across 20 hospitals in Taiwan, with the participation of more than 130 urologists. MCS-8 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction. The Company expects to analyze the trial data following completion of the treatment period and will share results in accordance with applicable disclosure requirements.
